BackTable Urology
Ep. 207 Integrating Clinical Trials into Routine Urology Practice with Dr. Behfar Ehdaie
Aditya Bagrodia
Yeah. I mean, it's one of those things that's obvious and it's not. I mean, this is separate, but perhaps related. At many institutions now, a blanket IRB for retrospective studies that pose zero risk to a patient are disallowed. Or biospecimen collection protocols may be challenging to get through. MTAs, DTAs between institutions can be a little bit complicated. And
0
💬
0
Comments
Log in to comment.
There are no comments yet.